公司资料
Cytokinetics 股价、新闻与催化剂
- 股票代码:
- CYTK
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
75.87 USD (+2.35%)
收盘价
最后更新: 2026年8月17日
9.63B USD
市值
股价为何变动
The latest monitored company update is “Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
公司概览
Muscle Biology Specialization
Cytokinetics develops and commercializes medicines that modulate muscle function. Its portfolio is centered on cardiac muscle biology and diseases in which altered contractility contributes directly to symptoms and clinical outcomes.
MYQORZO in Obstructive HCM
MYQORZO, or aficamten, is a cardiac myosin inhibitor approved in the United States and European Union for adults with symptomatic obstructive hypertrophic cardiomyopathy. The product launched in the United States in January 2026 and forms the company’s emerging commercial franchise.
Aficamten Lifecycle Development
Cytokinetics is seeking to broaden aficamten across hypertrophic cardiomyopathy. The Phase 3 ACACIA-HCM trial met its dual primary endpoints in symptomatic non-obstructive HCM, while MAPLE-HCM supports a supplemental application in obstructive disease and additional studies address Japanese patients.
Heart-Failure Pipeline
Omecamtiv mecarbil is a cardiac myosin activator in the confirmatory Phase 3 COMET-HF trial for symptomatic heart failure with severely reduced ejection fraction. This program extends the company’s muscle-directed approach beyond HCM.
未来催化剂
- Initial European launch of MYQORZO in Germany expected in the second quarter of 2026.
- FDA action on the aficamten supplemental NDA supported by MAPLE-HCM expected by November 14, 2026.
- Full results from the Phase 3 ACACIA-HCM trial to be presented at a medical congress.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。